55 research outputs found
スタチンはYAP制御を介してゲムシタビンの肝内胆管癌抑制効果を増強させる
Cholangiocarcinoma (CCA) is associated with high mortality rates because of its resistance to conventional gemcitabine-based chemotherapy. Hydroxy-methyl-glutaryl-coenzyme A reductase inhibitors (statins) reportedly exert anti-cancer effects in CCA and lower the risk of CCA; however, the underlying mechanism of these effects remains unclear. The proliferative and oncogenic activities of the transcriptional co-activator Yes-associated protein (YAP) are driven by its association with the TEA domain (TEAD) of transcription factors; thereby, upregulating genes that promote cell growth, inhibit apoptosis, and confer chemoresistance. This study investigated the effects of atorvastatin in combination with gemcitabine on the progression of human CCA associated with YAP oncogenic regulation. Both atorvastatin and gemcitabine concentration-dependently suppressed the proliferation of HuCCT-1 and KKU-M213 human CCA cells. Moreover, both agents induced cellular apoptosis by upregulating the pro-apoptotic marker BAX and downregulating the anti-apoptotic markers MCL1 and BCL2. Atorvastatin also significantly decreased the mRNA expression of the TEAD target genes CTGF, CYR61, ANKRD1, and MFAP5 in both CCA cell lines. A xenograft tumor growth assay indicated that atorvastatin and gemcitabine potently repressed human CCA cell-derived subcutaneous tumor growth by inhibiting YAP nuclear translocation and TEAD transcriptional activation. Notably, the anti-cancer effects of the individual agents were significantly enhanced in combination. These results indicate that gemcitabine plus atorvastatin could serve as a potential novel treatment option for CCA.博士(医学)・甲第778号・令和3年3月15日© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
スルフォラファンはNrf2 活性化作用を介し抗酸化ストレス作用、アセトアルデヒド代謝作用およびLPS/TLR4 シグナル経路を阻害することで四塩化炭素およびエタノール投与により誘発されるアルコール肝線維症を改善する
Alcoholic liver disease (ALD)-related fibrosis results from a variety of mechanisms including the accumulation of acetaldehyde, reactive oxygen species, and hepatic overload of endogenous lipopolysaccharide (LPS). Alcohol cessation is the therapeutic mainstay for patients with all stages of ALD, whereas pharmacological strategies for liver fibrosis have not been established. Sulforaphane, a phytochemical found in cruciferous vegetables, activates nuclear factor erythroid 2-related factor 2 (Nrf2) and exerts anticancer, antidiabetic, and antimicrobial effects; however, few studies investigated its efficacy in the development of ALD-related fibrosis. Herein, we investigated the effect of sulforaphane on acetaldehyde metabolism and liver fibrosis in HepaRG and LX-2 cells, human hepatoma and hepatic stellate cell lines, respectively, as well as in a mouse model of alcoholic liver fibrosis induced by ethanol plus carbon tetrachloride (EtOH/CCl₄). Sulforaphane treatment induced the activity of acetaldehyde-metabolizing mitochondrial aldehyde dehydrogenase in HepaRG cells and suppressed the acetaldehyde-induced proliferation and profibrogenic activity in LX-2 cells with upregulation of Nrf2-regulated antioxidant genes, including HMOX1, NQO1, and GSTM3. Moreover, sulforaphane attenuated the LPS/toll-like receptor 4-mediated sensitization to transforming growth factor-β with downregulation of NADPH oxidase 1 (NOX1) and NOX4. In EtOH/CCl₄-treated mice, oral sulforaphane administration augmented hepatic acetaldehyde metabolism. Additionally, sulforaphane significantly inhibited Kupffer cell infiltration and fibrosis, decreased fat accumulation and lipid peroxidation, and induced Nrf2-regulated antioxidant response genes in EtOH/CCl₄-treated mice. Furthermore, sulforaphane treatment blunted hepatic exposure of gut-derived LPS and suppressed hepatic toll-like receptor 4 signaling pathway. Taken together, these results suggest sulforaphane as a novel therapeutic strategy in ALD-related liver fibrosis.博士(医学)・甲第811号・令和4年3月15日© 2020 Elsevier Inc. All rights reserved
レンバチニブは実験的肝線維症において肝星細胞の活性化と類洞毛細血管化を阻害することにより肝線維化を抑制する。
Molecular targeted agents are pharmacologically used to treat liver fibrosis and have gained increased attention. The present study examined the preventive effect of lenvatinib on experimental liver fibrosis and sinusoidal capillarization as well as the in vitro phenotypes of hepatic stellate cells. LX-2, a human stellate cell line, was used for in vitro studies. In vivo liver fibrosis was induced in F344 rats using carbon tetrachloride by intraperitoneal injection for 8 weeks, and oral administration of lenvatinib was started two weeks after initial injection of carbon tetrachloride. Lenvatinib restrained proliferation and promoted apoptosis of LX-2 with suppressed phosphorylation of extracellular signal-regulated kinase 1/2 and AKT. It also down-regulated COL1A1, ACTA2 and TGFB1 expressions by inhibiting the transforming growth factor-β1/Smad2/3 pathway. Treatment with lenvatinib also suppressed platelet-derived growth factor-BB-stimulated proliferation, chemotaxis and vascular endothelial growth factor-A production, as well as basic fibroblast growth factor-induced LX-2 proliferation. In vivo study showed that lenvatinib attenuated liver fibrosis development with reduction in activated hepatic stellate cells and mRNA expression of profibrogenic markers. Intrahepatic neovascularization was ameliorated with reduced hepatic expressions of Vegf1, Vegf2 and Vegfa in lenvatinib-treated rats. Collectively, these results suggest the potential use of lenvatinib as a novel therapeutic strategy for liver fibrosis.博士(医学)・甲第812号・令和4年3月15日© 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited
アンジオテンシン受容体拮抗薬は、肝硬変ラットの骨格筋萎縮に対して、分岐鎖アミノ酸製剤による保護効果を増強する。
Scope: This study investigated the combined effect of the angiotensin II
(AT-II) receptor blocker losartan and branched-chain amino acids (BCAAs) on
skeletal muscle atrophy in rats with cirrhosis and steatohepatitis.
Method and Results: Fischer 344 rats are fed a choline-deficient l-amino
acid-defined (CDAA) diet for 12 weeks and treated with oral losartan (30 mg
kg−1 day−1) and/or BCAAs (Aminoleban EN, 2500 mg kg−1 day−1). Treatment
with losartan and BCAAs attenuated hepatic inflammation and fibrosis and
improved skeletal muscle atrophy and strength in CDAA-fed rats. Both agents
reduced intramuscular myostatin and pro-inflammatory cytokine levels,
resulting in inhibition of the ubiquitin–proteasome system (UPS) through
interference with the SMAD and nuclear factor-kappa B pathways,
respectively. Losartan also augmented the BCAA-mediated increase of skeletal
muscle mass by promoting insulin growth factor-I production and
mitochondrial biogenesis. Moreover, losartan decreased the intramuscular
expression of transcription factor EB (TFEB), a transcriptional inducer of E3
ubiquitin ligase regulated by AT-II. In vitro assays illustrated that losartan
promoted mitochondrial biogenesis and reduced TFEB expression in
AT-II-stimulated rat myocytes, thereby potentiating the inhibitory effects of
BCAAs on the UPS and caspase-3 cleavage.
Conclusion: These results indicate that this regimen could serve as a novel
treatment for patients with sarcopenia and liver cirrhosis.博士(医学)・甲第861号・令和5年3月15
アンジオテンシンII 受容体拮抗薬であるロサルタンは、レンバチニブによるヒト肝癌細胞への 細胞増殖抑制性および血管新生抑制効果の感性を向上させる
Molecular targeted therapy with lenvatinib is commonly offered to advanced hepatocellular carcinoma (HCC) patients, although it is often interrupted by adverse effects which require a reduction in the initial dose. Thus, an alternative lenvatinib-based therapy to compensate for dose reduction is anticipated. This study aimed to assess the effect of combination of low-dose of lenvatinib and the angiotensin-II (AT-II) receptor blocker losartan on human HCC cell growth. In vitro studies found that losartan suppressed the proliferation by inducing G1 arrest and caused apoptosis as indicated by the cleavage of caspase-3 in AT-II-stimulated HCC cell lines (Huh-7, HLE, and JHH-6). Losartan attenuated the AT-II-stimulated production of vascular endothelial growth factor-A (VEGF-A) and interleukin-8 and suppressed lenvatinib-mediated autocrine VEGF-A production in HCC cells. Moreover, it directly inhibited VEGF-mediated endothelial cell growth. Notably, the combination of lenvatinib and losartan augmented the cytostatic and angiostatic effects of the former at a low-dose, reaching those achieved with a conventional dose. Correspondingly, a HCC tumor xenograft assay showed that the oral administration of losartan combined with lenvatinib reduced the subcutaneous tumor burden and intratumor vascularization in BALB/c nude mice. These findings support that this regimen could be a viable option for patients intolerant to standard lenvatinib dosage.博士(医学)・甲第813号・令和4年3月15日© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
酢酸亜鉛とリファキシミンの併用療法による腸管バリアー機能維持によるエタノール誘発性肝線維化予防効果
BACKGROUND
Hepatic overload of gut-derived lipopolysaccharide dictates the progression of
alcoholic liver disease (ALD) by inducing oxidative stress and activating Kupffer
cells and hepatic stellate cells through toll-like receptor 4 signaling. Therefore,
targeting the maintenance of intestinal barrier integrity has attracted attention for
the treatment of ALD. Zinc acetate and rifaximin, which is a nonabsorbable
antibiotic, had been clinically used for patients with cirrhosis, particularly those
with hepatic encephalopathy, and had been known to improve intestinal barrier
dysfunction. However, only few studies focused on their efficacies in preventing
the ALD-related fibrosis development.
AIM
To investigate the effects of a combined zinc acetate with rifaximin on liver
fibrosis in a mouse ALD model.
METHODS
To induce ALD-related liver fibrosis, female C57BL/6J mice were fed a 2.5% (v/v)
ethanol-containing Lieber-DeCarli liquid diet and received intraperitoneal carbon
tetrachloride (CCl4) injection twice weekly (1 mL/kg) for 8 wk. Zinc acetate (100
mg/L) and/or rifaximin (100 mg/L) were orally administered during experimental
period. Hepatic steatosis, inflammation and fibrosis as well as intestinal
barrier function were evaluated by histological and molecular analyses. Moreover,
the direct effects of both agents on Caco-2 barrier function were assessed by in
vitro assays.RESULTSIn the ethanol plus CCl4-treated mice, combination of zinc acetate and rifaximin
attenuated oxidative lipid peroxidation with downregulation of Nox2 and Nox4.
This combination significantly inhibited the Kupffer cells expansion and the
proinflammatory response with blunted hepatic exposure of lipopolysaccharide
and the toll-like receptor 4/nuclear factor kB pathway. Consequently, liver
fibrosis and hepatic stellate cells activation were efficiently suppressed with
downregulation of Mmp-2, -9, -13, and Timp1. Both agents improved the atrophic
changes and permeability in the ileum, with restoration of tight junction proteins
(TJPs) by decreasing the expressions of tumor necrosis factor α and myosin light
chain kinase. In the in vitro assay, both agents directly reinforced ethanol or
lipopolysaccharide-stimulated paracellular permeability and upregulated TJPs in
Caco-2 cells.
CONCLUSION
Dual therapy with zinc acetate and rifaximin may serve as a strategy to prevent
ALD-related fibrosis by maintaining intestinal barrier integrity.博士(医学)・甲第862号・令和5年3月15
Different tumoricidal effects of interferon subclasses and p53 status on hepatocellular carcinoma development and neovascularization.
Interferon (IFN) is known as a multifunctional cytokine. The aim of this study was to examine the different effects of IFN subclass; namely, IFN-α and IFN-β, on hepatocellular carcinoma (HCC) growth especially in conjunction with angiogenesis that is known to play a pivotal role in the tumor growth. Furthermore, we also examined whether the p53 status in the tumor would alter the anti-tumoral effect of IFN against HCC growth since the p53 status reportedly affected the therapeutic effect of anti-angiogenic agents against cancer. When compared with IFN-α, IFN-β exerted a more potent inhibitory effect on HCC growth, even after the tumor was established, along with suppression of neovascularization in the tumor. A single treatment with clinically comparable low doses of IFN-β significantly inhibited HCC growth whereas the same dose of IFN-α did not. IFN-β also significantly suppressed the tumor growth both in the p53-wild and p53-mutant HCC cells. Our in vitro study revealed that IFN-β showed a more potent inhibitory effect on the endothelial cell proliferation than IFN-α as in the in vivo study. Collectively, IFN may be an alternative anti-angiogenic agent against HCC since it exerted a significant tumoricidal effect regardless of the host p53 status even at a low dose. A cautious approach may be also required in the clinical practice since even in a same IFN subclass (class-I), IFN-α and IFN-β exert tumoricidal effects of different magnitudes on HCC
リファキシミンは腸-肝臓-筋肉軸の調節により肝硬変ラットの骨格筋萎縮に対するL-カルニチンを介した予防効果を増強する
The gut‑liver‑muscle axis is associated with the
development of sarcopenia in liver cirrhosis. The present
study aimed to illustrate the combined effects of rifaximin
and L‑carnitine on skeletal muscle atrophy in cirrhotic rats
with steatohepatitis. For this purpose, a total of 344 Fischer
rats were fed a choline‑deficient L‑amino acid‑defined
(CD AA) diet with the daily oral administration of rifaximin
(100 mg/kg) and/or L‑carnitine (200 mg/kg), and measurements
of psoas muscle mass index and forelimb grip strength
were performed. After feeding for 12 weeks, blood samples,
and liver, ileum and gastrocnemius muscle tissues were
harvested. The effects of L‑carnitine on rat myocytes were
assessed using in vitro assays. Treatment with rifaximin
attenuated hyperammonemia and liver fibrosis in the
CD AA‑fed rats. Moreover, it improved intestinal permeability
with the restoration of tight junction proteins and
suppressed the lipopolysaccharide (LPS)‑mediated hepatic
macrophage activation and pro‑inflammatory response. In
addition, rifaximin prevented skeletal muscle mass atrophy
and weakness by decreasing intramuscular myostatin and
pro‑inflammatory cytokine levels. Moreover, rifaximin
synergistically enhanced the L‑carnitine‑mediated improvement
of skeletal muscle wasting by promoting the production
of insulin‑like growth factor‑1 and mitochondrial biogenesis,
resulting in the inhibition of the ubiquitin‑proteasome system
(UPS). The in vitro assays revealed that L‑carnitine directly
attenuated the impairment of mitochondrial biogenesis,
thereby inhibiting the UPS in rat myocytes that were stimulated
with LPS or tumor necrosis factor‑α. On the whole, the
present study demonstrates that the combination of rifaximin
with L‑carnitine may provide a clinical benefit for liver
cirrhosis‑related sarcopenia.博士(医学)・甲第863号・令和5年3月15
TGR5活性化はアナグリプチンによる糖尿病ラットに対する肝線維化抑制効果を増強する
Hyperglycemia and hyperinsulinemia activate the proliferative potential of hepatic stellate cells (HSCs) and promote hepatic fibrosis. Dipeptidyl peptidase-4 (DPP-4) inhibitors, antidiabetic agents, reportedly inhibit the HSC proliferation. Additionally, Takeda G protein-coupled receptor 5 (TGR5) agonists induce the systemic release of glucagon-like peptides from intestinal L cells, which maintains glycemic homeostasis. This study assessed the combined effect of TGR5 agonist and DPP-4 inhibitor on diabetes-based liver fibrosis development. Male diabetic rats received intraperitoneal injection of porcine serum (PS) to induce liver fibrosis, and they were orally administered the following agents: oleanolic acid (OA) as a TGR5 agonist, anagliptin (ANA) as a DPP-4 inhibitor, and a combination of both agents. Treatment with OA or ANA significantly improved glycemic status and attenuated intrahepatic steatosis and lipid peroxidation in diabetic rats. PS-induced liver fibrosis development was also drastically suppressed by treatment with either agent, and the combination of both reciprocally enhanced the antifibrotic effect. Fecal microbiome demonstrated that both agents inhibited the increase in the Firmicutes/Bacteroidetes ratio, an indicator of dysbiosis related to metabolic syndromes. Furthermore, ANA directly inhibited in vitro HSC proliferative and profibrogenic activities. Collectively, TGR5 agonist and DPP-4 inhibitor appears to be a novel strategy against liver fibrosis under diabetic conditions.博士(医学)・甲第766号・令和3年3月15日© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
胆汁酸吸着薬であるセベラマーは、内因性のリポポリサッカライドの過負荷を軽減して、非アルコール性脂肪性肝炎の肝線維化を改善する。
Despite the use of various pharmacotherapeutic strategies, fibrosis due to nonalcoholic steatohepatitis (NASH) remains an unsatisfied clinical issue. We investigated the effect of sevelamer, a hydrophilic bile acid sequestrant, on hepatic fibrosis in a murine NASH model. Male C57BL/6J mice were fed a choline-deficient, L-amino acid-defined, high-fat (CDHF) diet for 12 weeks with or without orally administered sevelamer hydrochloride (2% per diet weight). Histological and biochemical analyses revealed that sevelamer prevented hepatic steatosis, macrophage infiltration, and pericellular fibrosis in CDHF-fed mice. Sevelamer reduced the portal levels of total bile acid and inhibited both hepatic and intestinal farnesoid X receptor activation. Gut microbiome analysis demonstrated that sevelamer improved a lower α-diversity and prevented decreases in Lactobacillaceae and Clostridiaceae as well as increases in Desulfovibrionaceae and Enterobacteriaceae in the CDHF-fed mice. Additionally, sevelamer bound to lipopolysaccharide (LPS) in the intestinal lumen and promoted its fecal excretion. Consequently, the sevelamer treatment restored the tight intestinal junction proteins and reduced the portal LPS levels, leading to the suppression of hepatic toll-like receptor 4 signaling pathway. Furthermore, sevelamer inhibited the LPS-mediated induction of fibrogenic activity in human hepatic stellate cells in vitro. Collectively, sevelamer inhibited the development of murine steatohepatitis by reducing hepatic LPS overload.博士(医学)・甲第779号・令和3年3月15日© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
- …